Analyst firms · H.C. Wainwright · DRNA
H.C. Wainwright DRNA price target and rating history
Dicerna Pharmaceuticals, Inc. (DRNA) · Health Care
H.C. Wainwright rates Dicerna Pharmaceuticals, Inc. (DRNA) Neutral with a $38.25 price target, as of its latest action on Nov 18, 2021. It has published 4 rating actions on DRNA since June 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Neutral
- Price target
- $38.25
- Median target, all firms
- Too few
- Actions on DRNA
- 4
H.C. Wainwright price target on DRNA
Every H.C. Wainwright rating on DRNA
- Nov 18, 2021
- Aug 10, 2021
- Aug 6, 2021
- Jun 23, 2021
Questions about H.C. Wainwright and DRNA
- What is H.C. Wainwright's price target for DRNA?
- H.C. Wainwright's latest stated price target for Dicerna Pharmaceuticals, Inc. (DRNA) is $38.25, from its action on Nov 18, 2021.
- What is H.C. Wainwright's rating on DRNA?
- H.C. Wainwright rates DRNA Neutral, a neutral rating, as of Nov 18, 2021.
- When did H.C. Wainwright last change its view on DRNA?
- On Nov 18, 2021, H.C. Wainwright downgrades to Neutral from Buy, price target $32 to $38.25.
All H.C. Wainwright ratingsDRNA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.